Phar­ma in­dus­try rep­u­ta­tion scores pos­i­tive bump from in­sulin pric­ing news — Har­ris Poll

In­sulin drug prices and out-of-pock­et costs have been hot top­ics — and a drag on phar­ma in­dus­try rep­u­ta­tion — for years. But now re­cent news from a trio of drug­mak­ers pledg­ing to cap ex­tra costs for con­sumers helped push the en­tire in­dus­try rep­u­ta­tion up­ward, ac­cord­ing to The Har­ris Poll.

In polling meant to gauge the im­pact of the Sil­i­con Val­ley Bank crash and cri­sis, Har­ris found that the phar­ma in­dus­try was on­ly one of two in­dus­tries among 10 ver­ti­cals tracked to record a gain be­tween the time be­fore and af­ter the crash. Pos­i­tive view of phar­ma grew 49%, up 4% from the be­gin­ning to the end of March, the Har­ris sur­vey found. Gov­ern­ment was the oth­er sec­tor gain­ing with a 1% in­crease over the month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER